KR20250139419A - 세라마이드 및 이의 관상동맥질환 진단 용도 - Google Patents
세라마이드 및 이의 관상동맥질환 진단 용도Info
- Publication number
- KR20250139419A KR20250139419A KR1020257030977A KR20257030977A KR20250139419A KR 20250139419 A KR20250139419 A KR 20250139419A KR 1020257030977 A KR1020257030977 A KR 1020257030977A KR 20257030977 A KR20257030977 A KR 20257030977A KR 20250139419 A KR20250139419 A KR 20250139419A
- Authority
- KR
- South Korea
- Prior art keywords
- ceramide
- formula
- carbon atoms
- alkyl chain
- cer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012543P | 2014-06-16 | 2014-06-16 | |
| US62/012,543 | 2014-06-16 | ||
| US14/677,595 US9347960B2 (en) | 2014-06-16 | 2015-04-02 | Ceramides and their use in diagnosing CVD |
| US14/677,595 | 2015-04-02 | ||
| PCT/EP2015/063492 WO2015193325A2 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
| KR1020247004744A KR102864779B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247004744A Division KR102864779B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250139419A true KR20250139419A (ko) | 2025-09-23 |
Family
ID=54835950
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257030977A Pending KR20250139419A (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
| KR1020247004744A Active KR102864779B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
| KR1020177000864A Active KR102636885B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247004744A Active KR102864779B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
| KR1020177000864A Active KR102636885B1 (ko) | 2014-06-16 | 2015-06-16 | 세라마이드 및 이의 관상동맥질환 진단 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9347960B2 (enExample) |
| EP (2) | EP4089416A1 (enExample) |
| JP (1) | JP6774879B2 (enExample) |
| KR (3) | KR20250139419A (enExample) |
| CN (1) | CN106461685B (enExample) |
| CA (1) | CA2951578A1 (enExample) |
| MX (1) | MX380642B (enExample) |
| SA (1) | SA516380503B1 (enExample) |
| SG (1) | SG11201609621RA (enExample) |
| WO (1) | WO2015193325A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| US10996231B2 (en) * | 2014-12-16 | 2021-05-04 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| EP3714273A1 (en) * | 2017-11-20 | 2020-09-30 | Zora Biosciences OY | Methods for prediction and early detection of diabetes |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| EP3891509A1 (en) | 2018-12-06 | 2021-10-13 | Zora Biosciences OY | Biomarkers for cardiovascular events |
| CN112730638B (zh) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | 糖尿病合并心梗代谢标志物、检测试剂及试剂盒 |
| CN112986454A (zh) * | 2021-05-18 | 2021-06-18 | 天津云检医疗器械有限公司 | 急性心肌梗死的血清标志物、试剂盒和用途 |
| CN113495160B (zh) * | 2021-09-07 | 2021-11-19 | 宝枫生物科技（北京）有限公司 | 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用 |
| US20250052771A1 (en) * | 2021-12-17 | 2025-02-13 | National Research Council Of Canada | Diagnostic lipid biomarkers for covid-19 and methods for use thereof |
| CN116500179B (zh) * | 2023-04-21 | 2023-12-26 | 南京品生医疗科技有限公司 | 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统 |
| CN119198939B (zh) * | 2024-08-30 | 2025-06-03 | 北京大学第三医院（北京大学第三临床医学院） | 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012137A1 (en) | 2010-01-29 | 2011-08-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| DK2385374T4 (en) | 2010-05-05 | 2018-04-30 | Zora Biosciences Oy | LIPIDOMICS BIOMARKERS FOR ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE |
| CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP3190418B1 (en) | 2011-07-28 | 2019-05-01 | metanomics GmbH | Use of sm_sphingomyelin (d18:1, c16:0) as a marker for heart failure |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| US20160047829A1 (en) | 2012-10-18 | 2016-02-18 | Ruprecht-Karls-Universität Heidelberg | Means and Methods for Determining a Clearance Normalized Amount of a Metabolite Disease Biomarker in a Sample |
| CN105008931A (zh) | 2013-03-08 | 2015-10-28 | 佐拉生物科学公司 | 非高密度脂蛋白来源的cvd标志物 |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
-
2015
- 2015-04-02 US US14/677,595 patent/US9347960B2/en active Active
- 2015-06-16 SG SG11201609621RA patent/SG11201609621RA/en unknown
- 2015-06-16 MX MX2016016742A patent/MX380642B/es unknown
- 2015-06-16 KR KR1020257030977A patent/KR20250139419A/ko active Pending
- 2015-06-16 KR KR1020247004744A patent/KR102864779B1/ko active Active
- 2015-06-16 KR KR1020177000864A patent/KR102636885B1/ko active Active
- 2015-06-16 JP JP2016573763A patent/JP6774879B2/ja active Active
- 2015-06-16 EP EP22168767.6A patent/EP4089416A1/en active Pending
- 2015-06-16 CA CA2951578A patent/CA2951578A1/en not_active Abandoned
- 2015-06-16 EP EP15733650.4A patent/EP3155440B1/en active Active
- 2015-06-16 WO PCT/EP2015/063492 patent/WO2015193325A2/en not_active Ceased
- 2015-06-16 CN CN201580031908.1A patent/CN106461685B/zh active Active
-
2016
- 2016-05-19 US US15/159,650 patent/US10197582B2/en active Active
- 2016-12-15 SA SA516380503A patent/SA516380503B1/ar unknown
-
2018
- 2018-12-12 US US16/218,363 patent/US11474116B2/en active Active
-
2022
- 2022-02-10 US US17/668,927 patent/US11940453B2/en active Active
-
2024
- 2024-02-14 US US18/441,255 patent/US20240183866A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6774879B2 (ja) | 2020-10-28 |
| US20190113531A1 (en) | 2019-04-18 |
| US20150362513A1 (en) | 2015-12-17 |
| MX380642B (es) | 2025-03-12 |
| EP3155440B1 (en) | 2022-04-20 |
| KR102636885B1 (ko) | 2024-02-19 |
| US11474116B2 (en) | 2022-10-18 |
| EP3155440A2 (en) | 2017-04-19 |
| US11940453B2 (en) | 2024-03-26 |
| CA2951578A1 (en) | 2015-12-23 |
| CN106461685B (zh) | 2021-05-25 |
| MX2016016742A (es) | 2017-04-27 |
| US9347960B2 (en) | 2016-05-24 |
| KR102864779B1 (ko) | 2025-09-25 |
| EP4089416A1 (en) | 2022-11-16 |
| US20220163547A1 (en) | 2022-05-26 |
| KR20240023696A (ko) | 2024-02-22 |
| WO2015193325A2 (en) | 2015-12-23 |
| US20160266152A1 (en) | 2016-09-15 |
| CN106461685A (zh) | 2017-02-22 |
| SA516380503B1 (ar) | 2023-03-23 |
| WO2015193325A3 (en) | 2016-02-25 |
| KR20170018905A (ko) | 2017-02-20 |
| SG11201609621RA (en) | 2017-01-27 |
| JP2017519989A (ja) | 2017-07-20 |
| US10197582B2 (en) | 2019-02-05 |
| US20240183866A1 (en) | 2024-06-06 |
| BR112016028534A2 (pt) | 2017-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11940453B2 (en) | Ceramides and their use in diagnosing CVD | |
| Nikolic et al. | Metabolomics in hypertension | |
| Deidda et al. | Metabolomics, a promising approach to translational research in cardiology | |
| CN108445241B (zh) | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 | |
| Afshinnia et al. | Lipidomics and biomarker discovery in kidney disease | |
| WO2011063470A1 (en) | Lipid biomarkers for stable and unstable heart disease | |
| US20190086386A1 (en) | USE OF CERAMIDES AND LPLs IN DIAGNOSING CVD | |
| CN118409095A (zh) | 用于诊断冠状动脉狭窄程度的代谢标志物及其应用 | |
| JP2016532115A (ja) | 被験体において心不全を診断するための手段及び方法 | |
| KR102897948B1 (ko) | 심혈관계 이벤트용 바이오마커 | |
| EP3714273A1 (en) | Methods for prediction and early detection of diabetes | |
| EP2526426A1 (en) | Method for assaying diseases characterised by dyslipidemia | |
| HK40083140A (en) | Ceramides and their use in diagnosing cardiovascular diseases | |
| HK1230721B (en) | Ceramides and their use in diagnosing cvd | |
| HK1230721A1 (en) | Ceramides and their use in diagnosing cvd | |
| Ricciardi | Fibrillazione atriale nell’anziano: dalla valutazione clinica alle indagini dimetabolomica. Un approccio multidimensionale per lo studio di un’aritmia complessa. Atrial fibrillation in the elderly: From multidimensional assessment to a metabolomic insight. A complex approach for a complex arrhythmia. | |
| BR112016028534B1 (pt) | Composição compreendendo ceramidas, kits e métodos in vitro para determinar o risco do desenvolvimento de doenças ou complicações cardiovasculares, avaliar e escolher tratamentos | |
| Grau et al. | Bringing Human Serum Lipidomics | |
| Lindahl | Gaps in Our Biomarker Armamentarium: What Novel Biomarkers Might Be Synergistic in Patients with Acute Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE) |